Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
2017-003150-16Phase 2Active
- Sponsor
- University Hospital Ulm
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of copanlisib and rituximab in marginal zone B-cell lymphoma (MZL), splenic marginal zone lymphoma (SMZL), extranodal marginal zone B-cell lymphoma (EMZL) and 1 more, sponsored by University Hospital Ulm. Primary endpoint: Complete remission rate after induction therapy. Started Jun 2018; status: active.
02
Drugs
copanlisibrituximab
03
Conditions
marginal zone B-cell lymphoma (MZL)splenic marginal zone lymphoma (SMZL)extranodal marginal zone B-cell lymphoma (EMZL)nodal marginal zone B-cell lymphoma (NMZL)
Beyond the preview
Go deeper on 2017-003150-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003150-16.